Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)
Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)
Update of R&D expense guidance (now € 275 to € 300 million) following license agreements for felzartamab and MOR210
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.